Clinical Trial Update: Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial of Lu AF35700 in treatment-resistant schizophrenia was terminated; results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Schizophrenia

Drugs mentioned

• Lu AF35700 (Lu AF35700)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Treatment-resistant Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2020-01-07